Table 1.
Correlation of CKS2 expression with clinicopathologic features
| Characteristics | Total (n = 126) | CKS2 | P value | |
|---|---|---|---|---|
|
| ||||
| Negative (n = 55) | Positive (n = 71) | |||
| Age (years) | 0.214 | |||
| ≥ 60 | 37 (29.4%) | 13 (23.6%) | 24 (33.8%) | |
| < 60 | 89 (70.6%) | 42 (76.4%) | 47 (66.2%) | |
| T stage | 0.035 | |||
| 1 | 26 (20.6%) | 17 (30.9%) | 9 (12.7%) | |
| 2 | 87 (69.0%) | 32 (58.2%) | 55 (77.5%) | |
| 3 | 13 (10.3%) | 6 (10.9%) | 7 (9.9%) | |
| N stage | 0.334 | |||
| 0 | 49 (38.9%) | 24 (43.6%) | 25 (35.2%) | |
| 1 | 39 (31.0%) | 19 (34.5%) | 20 (28.2%) | |
| 2 | 30 (23.8%) | 10 (18.2%) | 20 (28.2%) | |
| 3 | 8 (6.3%) | 2 (3.6%) | 6 (8.5%) | |
| TNM stage | 0.156 | |||
| I | 10 (7.9%) | 6 (10.9%) | 4 (5.6%) | |
| II | 76 (60.3) | 36 (65.5%) | 40 (56.3%) | |
| III | 40 (31.7) | 13 (23.6%) | 27 (38.0%) | |
| Tumor differentiation | 0.016 | |||
| Well | 13 (10.3%) | 10 (18.2%) | 3 (4.2%) | |
| Moderate | 94 (74.6%) | 40 (72.7%) | 54 (76.1%) | |
| Poor | 19 (15.1%) | 5 (9.1%) | 14 (19.7%) | |
| ER | 0.322 | |||
| Positive | 81 (64.3%) | 38 (69.1%) | 43 (60.6%) | |
| Negative | 45 (35.7%) | 17 (30.9%) | 28 (39.4%) | |
| PR | 0.006 | |||
| Positive | 72 (57.1%) | 39 (70.9%) | 33 (46.5%) | |
| Negative | 54 (42.9%) | 16 (29.1%) | 38 (53.5%) | |
| HER2 | 0.140 | |||
| Positive | 36 (28.6%) | 12 (21.8%) | 24 (33.8%) | |
| Negative | 90 (71.4%) | 43 (78.2%) | 47 (66.2%) | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.